Last reviewed · How we verify
apatinib;etoposide and cisplatin
This combination uses apatinib (a tyrosine kinase inhibitor targeting VEGFR2) alongside etoposide and cisplatin (chemotherapy agents) to inhibit tumor angiogenesis while simultaneously inducing DNA damage and apoptosis.
This combination uses apatinib (a tyrosine kinase inhibitor targeting VEGFR2) alongside etoposide and cisplatin (chemotherapy agents) to inhibit tumor angiogenesis while simultaneously inducing DNA damage and apoptosis. Used for Small cell lung cancer (Phase 3 investigation), Advanced or metastatic malignancies (investigational).
At a glance
| Generic name | apatinib;etoposide and cisplatin |
|---|---|
| Sponsor | Third Military Medical University |
| Drug class | Tyrosine kinase inhibitor (apatinib) combined with chemotherapy (etoposide and cisplatin) |
| Target | VEGFR2 (apatinib); Topoisomerase II (etoposide); DNA (cisplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Apatinib selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), blocking tumor neovascularization and reducing blood supply to cancer cells. Etoposide is a topoisomerase II inhibitor that causes DNA strand breaks, while cisplatin is a platinum-based alkylating agent that cross-links DNA. The combination leverages anti-angiogenic and cytotoxic mechanisms to enhance therapeutic efficacy.
Approved indications
- Small cell lung cancer (Phase 3 investigation)
- Advanced or metastatic malignancies (investigational)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Hypertension
- Hand-foot skin reaction
- Peripheral neuropathy
Key clinical trials
- Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia (PHASE2)
- Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors (PHASE2)
- Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer (NA)
- Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas (PHASE2)
- Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. (PHASE3)
- A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer (PHASE3)
- Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |